(Q39819964)

14 September 2017

0 references

Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome (English)

1 reference

14 September 2017

0 references

myelodysplastic syndrome

1 reference

Maha A Badawi

1

1 reference

14 September 2017

Linda M Vickars

series ordinal

2

1 reference

14 September 2017

Jocelyn M Chase

series ordinal

3

1 reference

14 September 2017

Heather A Leitch

series ordinal

4

1 reference

14 September 2017

23 March 2010

1 reference

14 September 2017

Advances in Hematology

1 reference

14 September 2017

2010

1 reference

14 September 2017

164045

1 reference

Creative Commons Attribution 3.0 Unported

14 September 2017

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Mechanisms of iron loading and toxicity.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Intracellular labile iron.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Clinical issues in the management of patients with myelodysplasia

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Efficacy of lenalidomide in myelodysplastic syndromes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Iron toxicity and chelation therapy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

The World Health Organization (WHO) classification of the myeloid neoplasms

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Practical management of iron overload.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

International scoring system for evaluating prognosis in myelodysplastic syndromes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Iron-chelating therapy and the treatment of thalassemia.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Proposals for the classification of the myelodysplastic syndromes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Alternative treatment paradigm for thalassemia using iron chelators

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Oxidative status of platelets in normal and thalassemic blood.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2846339

Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome

20 August 2018

1 reference

12 December 2020

Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis

1 reference

12 December 2020

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

12 December 2020

The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload

1 reference

12 December 2020

Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia

1 reference

12 December 2020

Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia

1 reference

12 December 2020

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

12 December 2020

Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans

1 reference

12 December 2020

Consensus statement on iron overload in myelodysplastic syndromes

1 reference

12 December 2020

Desferrioxamine in the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/164045

1 reference

release_mchqeyuvbvhmjgxq6ylnqivdre

14 September 2017

0 references

1 reference

14 September 2017

1 reference